AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
226.82
+4.00 (1.80%)
Dec 19, 2025, 4:00 PM EST - Market closed
AbbVie Revenue
AbbVie had revenue of $15.78B in the quarter ending September 30, 2025, with 9.10% growth. This brings the company's revenue in the last twelve months to $59.64B, up 7.40% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$59.64B
Revenue Growth
+7.40%
P/S Ratio
6.73
Revenue / Employee
$1,084,436
Employees
55,000
Market Cap
400.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | 33.27B | 513.00M | 1.57% |
| Dec 31, 2018 | 32.75B | 4.54B | 16.08% |
| Dec 31, 2017 | 28.22B | 2.58B | 10.06% |
| Dec 31, 2016 | 25.64B | 2.78B | 12.16% |
| Dec 31, 2015 | 22.86B | 2.90B | 14.52% |
| Dec 31, 2014 | 19.96B | 1.17B | 6.23% |
| Dec 31, 2013 | 18.79B | 410.00M | 2.23% |
| Dec 31, 2012 | 18.38B | 936.00M | 5.37% |
| Dec 31, 2011 | 17.44B | 1.81B | 11.55% |
| Dec 31, 2010 | 15.64B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
| Abbott Laboratories | 43.84B |
ABBV News
- 2 days ago - Trump to announce new drug-pricing deals later today - Market Watch
- 4 days ago - AbbVie, several other pharma companies near MFN deal with Trump, sources say - Reuters
- 7 days ago - AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings - Seeking Alpha
- 11 days ago - AbbVie: Unique Mix Of Growth And Value - Seeking Alpha
- 14 days ago - OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development - GlobeNewsWire
- 18 days ago - AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 19 days ago - AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers - PRNewsWire
- 20 days ago - AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating - Seeking Alpha